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Novelty and Impact: This study shows the detrimental effect of de novo malignancies 
(DNMs) on survival of Italian liver transplant (LT) recipients as compared to corresponding 
LT recipients without DNM. This negative pattern was consistent for the most frequent 
cancer types, and it calls for close post-transplant follow-up to detect tumours at earlier 
stages when treatments are more effective. 
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Abstract  
In the setting of liver transplant (LT), the survival after the diagnosis of de novo 
malignancies (DNMs) has been poorly investigated. In this study, we assessed the impact 
of DNMs on survival of LT recipients as compared to corresponding LT recipients without 
DNM.  
A nested case-control study was conducted in a cohort of 2818 LT recipients enrolled in 
nine Italian centres between 1985 and 2014. Cases were 244 LT recipients who 
developed DNMs after LT. For each case, 2 controls matched for gender, age, and year at 
transplant were selected by incidence density sampling among cohort members without 
DNM. The survival probabilities were estimated using the Kaplan-Meier method. Hazard 
ratios (HRs) of death and 95% confidence intervals (CIs) were estimated using Cox 
proportional hazard models. 
The all-cancer 10-year survival was 43% in cases versus 70% in controls (HR=4.66; 95% 
CI: 3.17-6.85). Survival was impaired in cases for all the most frequent cancer types, 
including lung (HR=37.13; 95% CI: 4.98-276.74), non-Hodgkin lymphoma (HR=6.57; 95% 
CI: 2.15-20.01), head and neck (HR=4.65; 95% CI: 1.81-11.95), and colon-rectum 
(HR=3.61; 95% CI: 1.08-12.07). The survival gap was observed for both early and late 
mortality, although the effect was more pronounced in the first year after cancer diagnosis. 
No significant differences in survival emerged for Kaposi’s sarcoma and non-melanoma 
skin cancers. 
The survival gap herein quantified included a broad range of malignancies following LT 
and prompts close monitoring during the post-transplant follow-up in order to ensure early 
cancer diagnosis and to improve survival. 
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Introduction  
Solid-organ transplant recipients are known to be at higher risk of developing several 
cancer types, mainly virus-related malignancies, compared with the general population [1-
4]. The large number of investigations that have explored cancer incidence in transplant 
recipients has not been paralleled by investigations focused on the prognostic impact of de 
novo malignancies (DNMs) [5,6]. The few studies conducted in the setting of liver 
transplant (LT) have suggested that the increased tumour burden among LT recipients 
may substantially impair their overall survival [5,7,8]. The majority of these investigations, 
however, have carried out external comparisons, i.e., they evaluate the impact of cancer 
outcomes following LT with those observed in the general population [9,10].  
The use of immunosuppressive drugs and the possible limitation of treatment options in LT 
recipients may influence patient survival after a cancer diagnosis. Since LT recipients have 
already been shown to be at higher risk of death than the corresponding general 
population [6,11], they represent an optimal reference group to assess the impact of DNMs 
on survival of immune-suppressed LT recipients.  
In this study, we assessed the long-term effects of developing cancer on survival among 
Italian LT recipients. To this end, we compared the survival of LT recipients who 
developed DNMs with that of corresponding cohort members without a DNM. 
Materials and methods 
We conducted a nested case-control study taking advantage of a cohort of 3121 
individuals who underwent, between 1985 and 2014, LT in nine centres from all over Italy. 
LT recipients were excluded from this analysis if they met anyone of the following criteria: 
(1) history of a previous transplant (n=23); (2) a follow-up shorter than 30 days after LT
(n=232); (3) missing information on age, or age at LT below 18 years (n=32); (4) a cancer 
diagnosis other than hepatocellular cancer (HCC) within the 5 years preceding transplant 
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or within 30 days after LT (n=16). Thus, a total of 2818 LT recipients constituted the 
members of the cohort from which we selected cases and controls. 
Trained staff gathered appropriate information from medical records and checked data for 
accuracy and completeness in each of the nine transplant centres. Information on patients 
characteristics (e.g., sex, age at transplant, area of origin, and residence), and on 
transplant (e.g., transplant centre, date of LT, underlying disease, donor status) were 
retrieved using standard data collection forms. Data regarding follow-up and vital status 
were actively collected. 
Among the cohort members, 244 patients who developed DNMs after LT were identified 
as cases. Cancer diagnoses were ascertained as a result of clinical follow-up, 
histologically confirmed, and coded according to the International Classification of 
Diseases and Related Health Problems, 10th revision (ICD-10). Multiple primary tumours 
were included in the site-specific survival analyses. For LT recipients diagnosed with more 
than one DNM within the same ICD-10 group (e.g., colon-rectum ICD-10 codes: C18-20; 
head and neck: C00-14, C30-32; all: C00-97), only the first one was considered. For each 
cancer case, two control subjects were randomly selected using incidence density 
sampling from members of the cohort who did not have a DNM diagnosis at the time when 
the case was identified. Controls were matched to each case on gender, age at transplant 
(<40, 40-59, ≥60 years), and calendar year at transplant (± 1 year). We assigned to each 
control the same index date (date of diagnosis) as their matched case. 
For each person, time at risk was calculated as the time elapsed from the date of cancer 
diagnosis (or index date for controls) to the date of death, or to end of follow-up, whichever 
came first. The follow-up period was truncated at 10 years. The survival probabilities for all 
cancers combined, and for selected cancer types were estimated by means of the Kaplan-
Meier method, and the log-rank test was used to compare survival rates. Hazard ratios 
(HRs) of death in cases compared with controls, and corresponding 95% confidence 
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intervals (CIs) were estimated using Cox proportional hazard models stratified on the 
matched sets. The HRs were also examined within strata of selected variables using Cox 
proportional hazard models adjusted for matching factors. The Wald test was used to 
assess the heterogeneity of HRs by different characteristics. To evaluate differences in 
short-term and long-term survival, the HRs of death for 1-year and 10-year survival 
(conditioned to be alive at 1 year) after cancer diagnosis were estimated. The proportional 
hazard assumption was assessed graphically and by including interactions with follow-up 
time [12]. 
All statistical analyses were performed using the software SAS Version 9.4 (SAS Institute 
Inc., Cary, North Carolina, USA). 
 
Results 
Table 1 shows the distribution by selected characteristics of 244 LT recipients with a DNM 
(i.e., the cases) and corresponding 488 matched controls. The majority of study subjects 
were males (79.1%), between 40 and 59 years of age (69.7%), and had undergone LT 
between 1985 and 2000 (39.3%). Compared to controls, cases were more likely to be 
residents in northern Italy and more frequently reported a history of alcohol abuse. No 
differences emerged according to history of HBV or HCV infection, or of 
immunosuppressive therapy with Tacrolimus or with cyclosporine. Conversely, the use of 
mTOR inhibitors was documented in 18% of cases and in 9% of controls. 
The 244 cases were followed up for a median period of 3.7 years (interquartile range, IQR: 
1.8-7.1) before cancer diagnosis, and the median length of follow-up after cancer 
diagnosis was 2.0 years (IQR: 0.6-5.4). Among cases, the most frequent cancer types 
(other than non-melanoma skin cancers) were head and neck cancer (13.9%; Table 2), 
non-Hodgkin lymphoma (NHL; 12.7%), bronchus and lung cancer (11.5%), colon-rectum 
cancer (8.6%), and Kaposi’s sarcoma (KS; 6.1%). 
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Overall, 100 cases out of 244 (41.0%) and 65 controls out of 488 (13.3%) died during the 
follow-up period. Figure 1 illustrates the Kaplan-Meier estimates of overall survival 
probabilities after cancer diagnosis for all cases, as compared to their matched control 
subjects. Controls showed a higher overall survival rate than cases (the 5- and 10-year 
survival probabilities were 89% and 70% for controls; 54% and 43% for cases, p<0.01). In 
cases, the poorest survival was observed for lung cancer (Figure 2f): all cases died within 
5 years after diagnosis (median survival: 0.7 years, 95% CI: 0.3-2.4), whereas the 5-years 
survival for their matched controls was 89%. Five-year overall survival in cases was 64% 
for NHL (median survival: 6.5 years, 95% CI: 0.5-10.0; Figure 2a), 45% for colorectal 
cancer (median survival: 3.3 years, 95% CI: 1.9-10.0; Figure 2e), and 42% for head and 
neck cancer (median survival: 4.0 years, 95% CI: 1.1-10.0; Figure 2d), although it 
remained significantly worse than in their respective control group. Survival did not differ 
significantly between the two groups for non-melanoma skin cancers (Figure 2c) and KS 
(Figure 2b). 
Table 3 shows the HRs of death in cases versus their matched controls, according to 
selected cancer types. A 4.7-fold higher risk of death (95% CI: 3.17-6.85) was documented 
for all cancer sites, and the exclusion of patients with non-melanoma skin cancers did not 
substantially modify this risk estimate (HR=5.51, 95% CI: 3.59-8.46 for cases vs controls). 
The highest HR was found for cancer of bronchus and lung (HR=37.13, 95% CI: 4.98-
276.74), followed by NHL (HR=6.57, 95% CI: 2.15-20.01), head and neck cancers 
(HR=4.65, 95% CI: 1.81-11.95), and colorectal cancer (HR=3.61, 95% CI: 1.08-12.07). 
Conversely, no statistically significant difference in risks emerged for KS or non-melanoma 
skin cancer. The HR of death for cases of all cancer types was significantly higher than for 
controls considering both early (i.e., at 1-year after cancer diagnosis) and late mortality 
(i.e., at 10-year after cancer diagnosis, conditioned to be alive after 1 year) (Table 3). 
However, the negative prognostic effect of DNMs was particularly evident in the early 
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mortality period (HR=5.93, 95% CI: 3.37-10.43). In particular, for cases with NHL 
(HR=20.00, 95% CI: 2.56-156.24) or head and neck cancer (HR=5.44, 95% CI: 1.46-
20.21), the survival gap was restricted to the first year after diagnosis. Conversely, for 
cases with colon-rectum (HR=29.85, 95% CI: 3.26-273.07) and bronchus and lung 
(HR=17.41, 95% CI: 4.56-66.52) cancers, the differences in the death risk emerged only 
after one year following diagnosis. No statistically significant differences in survival were 
observed for KS and for non-melanoma skin cancer throughout the entire follow-up period. 
No heterogeneity in HRs of death in cases of all cancer sites versus controls was detected 
across strata of gender, age at LT, year at transplant, area of residence, history of HBV or 
HCV infection, history of alcohol abuse, or use of immunosuppressive drugs (Table 4). 
  
Discussion  
The results of this study showed a detrimental effect of DNMs on the risk of death of LT 
recipients, as compared to corresponding LT recipients without DNM. This pattern was 
consistent for all the most frequent cancer types, with the exception of KS and non-
melanoma skin cancer. The survival gap was observed during both the early and the late 
mortality periods, even though the effect was more pronounced in the early period. 
The majority of previous investigations on survival after cancer in LT recipients showed a 
worse survival in LT population by comparing their observed results with those 
documented in the general population [9,10]. However, LT recipients differed from the 
general population for a wide spectrum of risk factors. Indeed, several risk factors are 
transplant-specific, and a substantial role is played by immunosuppressive regimens used 
to prevent the organ rejection [13]. The present study evidenced that, even compared with 
corresponding LT recipients, the occurrence of a DNM after LT carried a poor prognosis, 
with over 50% of LT recipients dying within 5 years from diagnosis. 
     ht. All rights reserved.
 
 
Although DNM has been reported in some investigations as a major cause of late mortality 
after LT [7,14,15], few studies have evaluated the effects of cancer on survival comparing 
LT recipients who developed DNMs with corresponding LT recipients who did not 
[8,16,17]. Moreover, none of these investigations have assessed cancer outcomes starting 
from the date of cancer diagnosis. In agreement with our findings, a previous report 
conducted in United States found that patients with a malignancy had a significantly lower 
survival after LT than control patients without neoplasm [16]. These results were further 
supported by a Spanish case-control study, though patients with and without cancer were 
not matched for gender and age [8]. In addition, a recent investigation reported that patient 
survival was diminished only in the subset of patients with DNM excluding non-melanoma 
skin cancer, compared with patients without cancer [17]. 
In the present type/site-specific analyses, the probability of survival was impaired in LT 
recipients with DNM for a broad range of malignancies. In accordance with other studies 
[16,18], the lowest survival probability was found for lung cancer patients – a neoplasm 
known for a generally poor prognosis. Nonetheless, the survival gap emerged also for 
other cancers that frequently occur after LT, for instance NHL and colon-rectum cancer.  
Our findings are in substantial agreement with prior evidence from studies on cancer 
outcomes among LT recipients [9,10,16]. A population-based analysis comparing 
outcomes of de novo cancer cases from the Israel Penn International Transplant Tumor 
Registry with those of the general population found a worse survival in transplant patients 
for several cancer types, including colorectal, lung, breast, prostate, and bladder cancers 
[10]. There is substantial variability in reported survival after post-transplant 
lymphoproliferative disease (PTLD), with median survival as low as two months in one 
report [19], likely due to heterogeneity in risk characteristics of PTLD. On the other hand, 
longer median survival intervals were noted in other LT investigations [7,20], with survival 
rates similar to those documented in the present study. As shown also in our previous 
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work [21], survival after head and neck cancer ranked among the least favourable in our 
LT population. We could not conduct analysis according to head and neck cancer subtype 
due to an insufficient number of cases, but there is a chance that the impaired survival 
reflected the predominance of types with poor prognosis. The survival analyses revealed 
that, for NHL and head and neck cancer, the survival gap was concentrated in the first 
year after diagnosis, pointing to the possibility of later stage diseases or less effective 
treatment protocols. In this study, non-melanoma skin cancers represented the most 
common DNM, a finding that is generally consistent among published reports [8,22]. We 
found no differences in survival rates between LT recipients with and without DNM over 
the entire period. Similarly, a case-control study showed that patients with skin cancer 
after LT had similar long-term survival when compared with patients without neoplasm 
[16]. In addition, another study reported that the survival after diagnosis of post-transplant 
DNM was better for skin cancer cases as compared to those with other DNMs [8]. 
The worse survival related to DNMs among LT recipients is thought to be the 
consequence of continuous immunosuppression that may give rise to increased 
proliferation and spread of the tumour, which results in more advanced stages of disease 
at occurrence, precluding surgical or chemo-radiotherapy options [7,23]. Close monitoring 
during the post-transplant follow-up year in this population is worth considering in order to 
detect tumours at earlier stages, allow more effective treatments, and improve survival. 
Some study limitations need to be mentioned. The lack of completeness of cancer case 
ascertainment was possible as diagnoses were registered on the basis of medical records. 
We could not perform a linkage with population-based cancer registries for all LT 
recipients. However, the strict clinical follow-up of these patients is likely to limit the lack of 
completeness of cancer ascertainment. Furthermore, despite the relatively large sample 
size, the study has still limited power to detect associations for specific cancer types and 
results should be interpreted with caution. Despite these limitations, this is the only study 
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that compared the survival of LT recipients with and without DNM starting from the date of 
diagnosis. The choice of this approach allowed us to provide an important perspective on 
evaluation of post-transplant cancer outcomes on long term survival among LT recipients. 
Moreover, all study participants were derived from a defined cohort over a defined time 
window and controls were matched to cases by age, sex, and year at transplant. Other 
important strengths include the relatively large sample size that allowed analyses by 
cancer type, the length of follow-up period, and the multicentric nature of the study.  
In conclusion, the findings of the present study further support the negative impact of DNM 
on survival among LT recipients. Targeted efforts to reduce the burden of post-transplant 
malignancies may improve long-term outcomes, and the implementation of specific 
interventions for this population as an attempt to ensure early cancer diagnosis should be 
considered. 
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Table 1. Distribution of 244 cases and 488 corresponding controls, according to matching 
variables and selected characteristics. 
 
Table 2. Distribution of 244 cases according to cancer types. 
 
Table 3. Hazard ratios (HRs) of death with corresponding 95% confidence intervals (CIs) 
in cases versus controls, according to selected cancer types and time since cancer 
diagnosis. 
 
Table 4. Hazard ratios (HRs) of death with corresponding 95% confidence intervals (CIs) 
in cases versus controls across strata of selected characteristics. 









Figure 2. Kaplan-Meier estimates of survival probabilities for cases of non-Hodgkin 
lymphoma (A), Kaposi’s Sarcoma (B), non-melanoma skin (C), head and neck (D), colon-
rectum (E), and bronchus and lung (F) cancers, and corresponding controls. 




Table 1. Distribution of 244 cases and 488 corresponding controls, according to matching 
variables and selected characteristics 
 Cases Controls 
 No. (%) No. (%) 
Sex   
Male 193 (79.1) 386 (79.1) 
Female 51 (20.9) 102 (20.9) 
Age at transplant (years)   
<40 27 (11.1) 54 (11.1) 
40-59 170 (69.7) 340 (69.7) 
≥60 47 (19.3) 94 (19.3) 
Median (IQR) 53 (48-58) 52 (45-58) 
Calendar year at transplant   
1985-2000 96 (39.3) 192 (39.3) 
2001-2005 80 (32.8) 171 (35.0) 
2006-2012 68 (27.9) 125 (25.6) 
Area of residence   
Northern Italy 70 (28.7) 100 (20.5) 
Central Italy 63 (25.8) 113 (23.2) 
Southern Italy 111 (45.5) 273 (55.9) 
Abroad 0 (0.0) 2 (0.4) 
History of HBV infection   
No 136 (55.7) 273 (55.9) 
Yes 108 (44.3) 215 (44.1) 
History of HCV infection   
No 140 (57.4) 247 (50.6) 
Yes 104 (42.6) 241 (49.4) 
History of alcohol abuse   
No 156 (63.9) 374 (76.6) 
Yes 88 (36.1) 114 (23.4) 
Ever use of Cyclosporinea   
No 124 (54.4) 248 (54.1) 
Yes 104 (45.6) 210 (45.9) 
Ever use of Tacrolimusa   
No 71 (31.1) 148 (32.3) 
Yes 157 (68.9) 310 (67.7) 
Ever use of mTOR inhibitorsa   
No 187 (82.0) 417 (91.0) 
Yes 41 (18.0) 41 (9.0) 
aThe sum does not add up to the total because of missing values.  
Abbreviations: IQR, Interquartile Range. 




Table 2. Distribution of 244 cases according to cancer types 
  Cases 
Cancer typea ICD-10 codes No. % 




Non-hodgkin lymphoma C82-85, C96 31 12.7 
Leukaemia C91-95 3 1.2 
Hodgkin’s lymphoma C81 2 0.8 
Multiple myeloma C90 1 0.4 
Solid tumors  
 
147 60.2 
Head and neck C00-14, C30-32 34 13.9 
Bronchus and lung C34 28 11.5 
Colon-rectum C18-20 21 8.6 
Bladder C67, D09.0,D30.3,D41.4  9 3.7 
Esophagus C15 8 3.3 
Stomach C16 7 2.9 
Skin melanoma C43 7 2.9 
Liver C22 6 2.5 
Breast female C50 4 1.6 
Kidney C64 4 1.6 
Thyroid gland C73 4 1.6 
Pancreas C25 3 1.2 
Cervix uteri C53 3 1.2 
Prostate  C61 2 0.8 
Testis C62 2 0.8 
Small intestine C17 1 0.4 
Bone and articular cartilage C41 1 0.4 
Mesothelioma C45 1 0.4 
Corpus uteri C54-55 1 0.4 
Penis C60 1 0.4 
Other/unspecified urinary organs  C68 1 0.4 
Brain C71 1 0.4 
Adrenal gland C74 2 0.8 
Unspecified sites C76-C80 3 1.2 
Skin non-melanoma C44 50 20.5 
All but skin non-melanoma  197 80.7 
All  244 100.0 
aThe sums can exceed the total because some patients were diagnosed with more than 
one malignancy. For LT recipients diagnosed with more than one malignancy within the 
same ICD-10 group (e.g., colon-rectum ICD-10 codes: C18-20; head and neck: C00-14, 
C30-32; all: C00-97) only the first one was considered. 
Abbreviations: LT, liver transplant; PTLD, post-transplant lymphoproliferative diseases. 




Table 3. Hazard ratios (HRs) of death with corresponding 95% confidence intervals (CIs) in cases versus controls, according to selected 





 10-year Survival,  
Conditioned to be Alive at 1 yr 
 Cases   Controls
c






















Kaposi’s sarcoma 3 20.0  6 20.0  1.23 (0.27-5.57)  2.00 (0.13-31.97)  0.43 (0.05-3.69) 
PTLD 18 48.7  12 16.2  6.85 (2.54-18.49)  13.00 (2.93-57.60)  2.11 (0.68-6.56) 
Non-hodgkin lymphoma 14  45.2  10 16.1  6.57 (2.15-20.01)  20.00 (2.56-156.24)  1.45 (0.41-5.09) 
Solid tumors 70 47.6  36 12.2  6.28 (3.76-10.48)  6.76 (3.35-13.66)  4.79 (2.85-8.06) 
Head and neck 17 50.0  11 16.2  4.65 (1.81-11.95)  5.44 (1.46-20.21)  2.75 (0.99-7.60) 
Bronchus and lung 21 75.0  7 12.5  37.13 (4.98-276.74)  -  17.41 (4.56-66.52) 
Colon-rectum 9 42.9  4 9.5  3.61 (1.08-12.07)  1.79 (0.36-8.97)  29.85 (3.26-273.07) 
Skin non-melanoma 13 26.0  14 14.0  2.23 (0.89-5.61)  0.55 (0.06-5.39)  2.26 (0.98-5.21) 
All but skin non-melanoma 89 45.2  52 13.2  5.51 (3.59-8.46)  7.35 (3.99-13.55)  3.41 (2.17-5.34) 
All 100 41.0  65 13.3  4.66 (3.17-6.85)  5.93 (3.37-10.43)  3.01 (2.02-4.49) 
aEstimated using Cox proportional hazard models stratified on the matched sets; bAdjusted for gender, age at transplant, and year at 
transplant; cReference category. 
Abbreviations: PTLD, Post-transplant lymphoproliferative diseases. 
 
 




Table 4. Hazard ratios (HRs) of death with corresponding 95% confidence intervals (CIs) 
in cases versus control across strata of selected characteristics 
 Cases  Controlsb   















Sex        
Male 83 43.0  52 13.5 4.42 (3.11-6.28)  
Female 17 33.3  13 12.8 3.14 (1.51-6.53) p=0.40 
Age at transplant (years)       
<40 8 29.6  4 7.4 6.04 (1.77-20.61)  
40-59 78 45.9  50 14.7 4.08 (2.85-5.83)  
≥60 14 29.8  11 11.7 3.82 (1.67-8.74) p=0.80 
Calendar year at transplant       
1985-2000 47 49.0  39 20.3 3.20 (2.09-4.91)  
2001-2005 34 42.5  21 12.3 4.03 (2.30-7.04)  
2006-2012 19 27.9  5 4.0 11.56 (4.18-31.93) p=0.07 
Area of residence        
Northern Italy 30 42.9  12 12.0 5.64 (2.71-11.72)  
Central Italy 28 44.4  11 9.7 6.04 (2.96-12.33)  
Southern Italy 42 37.8  42 15.4 3.55 (2.30-5.48) p=0.31 
History of HBV infection       
No 49 36.0  37 13.6 3.45 (2.24-5.31)  
Yes 51 47.2  28 13.0 4.76 (2.99-7.60) p=0.32 
History of HCV infection       
No 55 39.3  25 10.1 4.93 (3.05-7.96)  
Yes 45 43.3  40 16.6 3.77 (2.45-5.80) p=0.38 
History of alcohol abuse       
No 69 44.2  50 13.4 4.94 (3.41-7.15)  
Yes 31 35.2  15 13.1 3.11 (1.65-5.85) p=0.18 
Ever use of Cyclosporinec       
No 40 32.3  20 8.1 5.19 (3.02-8.92)  
Yes 48 46.2  30 14.3 4.31 (2.71-6.85) p=0.60 
Ever use of Tacrolimusc       
No 38 53.5  15 10.1 6.74 (3.69-12.30)  
Yes 50 31.9  35 11.3 3.79 (2.44-5.87) p=0.13 
Ever use of mTOR inhibitorsc       
No 76 40.6  45 10.8 4.73 (3.26-6.88)  
Yes 12 29.3  5 12.2 6.25 (1.92-20.35) p=0.58 
aAdjusted for gender, age at transplant, and year at transplant; bReference category; cThe 





















Solid-organ transplant recipients are at higher risk of developing several cancer types compared with 
the general population. The prognostic impact of de novo malignancies (DNMs) in these patients 
remain poorly investigated, however. This study shows the detrimental effect of DNMs on survival of 
liver transplant (LT) recipients as compared to matched LT recipients without DNM. The all-cancer 
10-year survival was 43% versus 70% in controls. This pattern was consistent for all the most 
frequent cancer types, except KS and non-melanoma skin cancer. The findings call for close post-
transplant follow-up to detect tumours at earlier stages when treatments are more effective. 
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